Ascendis Pharma A/S
Ascendis Pharma A/S is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism on August 15, 2027. There are 4 upcoming events on record.
Ascendis Pharma A/S generates cash from operations, so a burn-based runway figure does not apply.
Across 9 concluded trials, 78% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| August 15, 2027 | A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism | Trial Milestone | Phase 3 |
| September 15, 2027 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. | Trial Milestone | Phase 2 |
| December 15, 2027 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia | Trial Milestone | Phase 2 |
| February 15, 2028 | Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders | Trial Milestone | Phase 3 |
Track ASND alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ASND in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.